Background Only few studies have assessed safety of in utero exposure to glatiramer
acetate (GA). Following a previous study assessing the safety of interferon beta (IFNB) …

With the increasing incidence of multiple sclerosis (MS) in women and the earlier use of
disease modifying therapy (DMT), issues surrounding DMT and pregnancy are a regular …

Background: Only limited data are available on whether glatiramer acetate exposure during
pregnancy has an effect on perinatal outcome. Objective: To determine the effect of …

Multiple sclerosis (MS) is a demyelinating and neurodegenerative disease of the central
nervous system (CNS), most probably autoimmune in origin, usually occurring in young …

Multiple sclerosis (MS) is the most common disabling neurological disease in young women
of childbearing age and has an increasing incidence [1]. Recently Salminen et al.[2] …

Background: Appropriate counseling and treatment for women with multiple sclerosis (MS)
who may become pregnant requires an understanding of the effects of exposure to disease …

Background There is still uncertainty about the management of pregnant women exposed to
immunomodulatory therapy for treatment of multiple sclerosis (MS) in pregnancy. Objective …

Background: Glatiramer acetate is a US FDA category B drug with regard to use by pregnant
women with multiple sclerosis (MS). There are no data currently available for the continuous …

Objective: The objective of this study was to evaluate exposure to disease-modifying
therapies (DMTs) during pregnancy in 335 pregnancies of multiple sclerosis (MS) patients …

Objective: To systematically review the literature regarding safety of disease-modifying drug
(DMD) use during pregnancy on perinatal and developmental outcomes in offspring of …